Review of 5-HT4R ligands: State of art and clinical applications

Current Topics in Medicinal Chemistry

Volumn 10, Issue 5, 2010, Pages 527-553

  Bureau, Ronan ^a   Boulouard, Michel ^b   Dauphin, François ^b   Lezoualc'h, Frank ^c   Rault, Sylvain ^a  

^a CENTRE D ETUDES ET DE RECHERCHE SUR LE MÉDICAMENT DE NORMANDIE   (France)

^b UNIVERSITÉ DE CAEN   (France)

^c INSERM   (France)

Author keywords

5 ht4 receptor ligands; Agonists; Antagonists; Clinical applications; Serotonin

Indexed keywords

1 (4 AMINO 5 CHLORO 2 METHOXYPHENYL) 3 (1 BUTYL 4 PIPERIDINYL) 1 PROPANONE; 1 METHYL 3 INDOLECARBOXYLIC ACID [1 [2 (METHYLSULFONYLAMINO)ETHYL] 4 PIPERIDINYLMETHYL] ESTER; 4 AMINO 5 CHLORO N [(HEXAHYDRO 1H PYRROLIZIN 1 YL)METHYL] 2 METHOXYBENZAMIDE; ABT 224; AU 130; BENZAMIDE DERIVATIVE; CISAPRIDE; CJ 033466; CLEBOPRIDE; FABESETRON; INDAZOLE DERIVATIVE; ITASETRON; KDR 5169; METOCLOPRAMIDE; MOSAPRIDE CITRATE; PIBOSEROD; QUINOLONE DERIVATIVE; RENZAPRIDE; RS 100302; SC 52491; SC 54750; SEROTONIN 4 AGONIST; SEROTONIN 4 ANTAGONIST; SEROTONIN 4 RECEPTOR; SL 650155; TD 5108; TEGASEROD; TROPISETRON; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZACOPRIDE; LIGAND; SEROTONIN AGONIST; SEROTONIN ANTAGONIST;

ADRENAL GLAND; AREA UNDER THE CURVE; BINDING AFFINITY; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; CONSTIPATION; DIGESTIVE SYSTEM; DRUG RECEPTOR BINDING; HEART ATRIUM FIBRILLATION; HUMAN; IRRITABLE COLON; MICTURITION; NONHUMAN; PERIPHERAL NERVOUS SYSTEM; PROTEIN EXPRESSION; REVIEW; STOMACH EMPTYING; STOMACH PARESIS; STRUCTURE ACTIVITY RELATION; VOMITING; CHEMISTRY; DRUG ANTAGONISM; DRUG POTENTIATION; METABOLISM;

HUMANS; LIGANDS; RECEPTORS, SEROTONIN, 5-HT4; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77950572117     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802610791111551     Document Type: Review

References (197)

1. Hannon, J.; Hoyer, D. Molecular biology of 5-HT receptors. Behav. Brain Res., 2008, 195(1), 198-213.
2. Bockaert, J.; Claeysen, S.; Compan, V.; Dumuis, A. 5-HT(4) receptors: history, molecular pharmacology and brain functions. Neuropharmacology, 2008, 55(6), 922-931.
3. King, M. V.; Marsden, C. A.; Fone, K. C. A role for the 5-HT(1A), 5-HT4 and 5-HT6 receptors in learning and memory. Trends Pharmacol. Sci., 2008, 29(9), 482-492.
4. Maillet, M.; Robert, S. J.; Lezoualc'h, F. New insights into serotonin 5-HT4 receptors: a novel therapeutic target for Alzheimer's disease? Curr. Alzheimer Res., 2004, 1(2), 79-85.
5. Bockaert, J.; Sebben, M.; Dumuis, A. Pharmacological characterization of 5-hydroxytryptamine4(5-HT4) receptors positively coupled to adenylate cyclase in adult guinea pig hippocampal membranes: effect of substituted benzamide derivatives. Mol. Pharmacol., 1990, 37(3), 408-411. (Pubitemid 20115599)
6. Dumuis, A.; Bouhelal, R.; Sebben, M.; Cory, R.; Bockaert, J. A nonclassical 5-hydroxytryptamine receptor positively coupled with adenylate cyclase in the central nervous system. Mol. Pharmacol., 1988, 34(6), 880-887. (Pubitemid 19014410)
7. Kaumann, A. J. Piglet sinoatrial 5-HT receptors resemble human atrial 5-HT4-like receptors. Naunyn Schmiedebergs Arch. Pharmacol., 1990, 342(5), 619-622.
8. Baxter, G. S.; Craig, D. A.; Clarke, D. E. 5-Hydroxytryptamine4 receptors mediate relaxation of the rat oesophageal tunica muscularis mucosae. Naunyn Schmiedebergs Arch. Pharmacol., 1991, 343(5), 439-446.
9. Elswood, C. J.; Bunce, K. T.; Humphrey, P. P. Identification of putative 5-HT4 receptors in guinea-pig ascending colon. Eur. J. Pharmacol., 1991, 196(2), 149-155.
10. Bender, E.; Pindon, A.; van Oers, I.; Zhang, Y. B.; Gommeren, W.; Verhasselt, P.; Jurzak, M.; Leysen, J.; Luyten, W. Structure of the human serotonin 5-HT4 receptor gene and cloning of a novel 5-HT4 splice variant. J. Neurochem., 2000, 74(2), 478-489. (Pubitemid 30053719)
11. Hiroi, T.; Hayashi-Kobayashi, N.; Nagumo, S.; Ino, M.; Okawa, Y.; Aoba, A.; Matsui, H. Identification and characterization of the human serotonin-4 receptor gene promoter. Biochem. Biophys. Res. Commun. 2001, 289, (2), 337-344. (Pubitemid 33141058)
12. Maillet, M.; Gastineau, M.; Bochet, P.; Asselin-Labat, M. L.; Morel, E.; Laverriere, J. N.; Lompre, A. M.; Fischmeister, R.; Lezoualc'h, F. Functional studies of the 5'-untranslated region of human 5-HT4 receptor mRNA. Biochem. J., 2005, 387(Pt 2), 463-471.
13. Medhurst, A. D.; Lezoualc'h, F.; Fischmeister, R.; Middlemiss, D. N.; Sanger, G. J. Quantitative mRNA analysis of five C-terminal splice variants of the human 5-HT4 receptor in the central nervous system by TaqMan real time RT-PCR. Brain Res. Mol. Brain Res., 2001, 90(2), 125-134.
14. Langlois, M.; Fischmeister, R. 5-HT4 receptor ligands: applications and new prospects. J. Med. Chem., 2003, 46(3), 319-344. (Pubitemid 36139783)
15. Mialet, J.; Berque-Bestel, I.; Sicsic, S.; Langlois, M.; Fischmeister, R.; Lezoualc'h, F. Pharmacological characterization of the human 5-HT4(d) receptor splice variant stably expressed in Chinese hamster ovary cells. Br. J. Pharmacol., 2000, 131(4), 827-835.
16. Pindon, A.; Van Hecke, G.; Josson, K.; Van Gompel, P.; Lesage, A.; Leysen, J. E.; Jurzak, M. Internalization of human 5-HT4a and 5-HT4b receptors is splice variant dependent. Biosci. Rep., 2004, 24(3), 215-223.
17. Castro, L.; Mialet-Perez, J.; Guillemeau, A.; Stillitano, F.; Zolk, O.; Eschenhagen, T.; Lezoualc'h, F.; Bochet, P.; Fischmeister, R. Differential functional effects of two 5-HT4 receptor isoforms in adult cardiomyocytes. J. Mol. Cell. Cardiol., 2005, 39(2), 335-344.
18. Robert, S.; Maillet, M.; Morel, E.; Launay, J. M.; Fischmeister, R.; Mercken, L.; Lezoualc'h, F. Regulation of the amyloid precursor protein ectodomain shedding by the 5-HT4 receptor and Epac. FEBS Lett., 2005, 579(5), 1136-1142.
19. Robert, S. J.; Lezoualc'h, F. Distinct functional effects of human 5-HT4 receptor isoforms on beta-amyloid secretion. Neurodegener. Dis., 2008, 5(3-4), 163-165.
20. 4 receptors as targets for drug discovery for dementia. The Serotonin Receptors: From Molecular Pharmacology to Human Therapeutics. The Humana Press. Roth BL. Chap. 15, 2006, p 459-479.
21. Eglen, R. M.; Wong, E. H.; Dumuis, A.; Bockaert, J. Central 5-HT4 receptors. Trends Pharmacol. Sci., 1995, 16(11), 391-398.
22. Bonaventure, P.; Hall, H.; Gommeren, W.; Cras, P.; Langlois, X.; Jurzak, M.; Leysen, J. E. Mapping of serotonin 5-HT(4) receptor mRNA and ligand binding sites in the post-mortem human brain. Synapse, 2000, 36(1), 35-46.
23. Matsumoto, M.; Togashi, H.; Mori, K.; Ueno, K.; Ohashi, S.; Kojima, T.; Yoshioka, M. Evidence for involvement of central 5-HT(4) receptors in cholinergic function associated with cognitive processes: behavioral, electrophysiological, and neurochemical studies. J. Pharmacol. Exp. Ther., 2001, 296(3), 676-682. (Pubitemid 32187334)
24. Meneses, A.; Hong, E. Effects of 5-HT4 receptor agonists and antagonists in learning. Pharmacol., Biochem. Behav., 1997, 56, (3), 347-351. (Pubitemid 27145811)
25. Lelong, V.; Dauphin, F.; Boulouard, M. RS 67333 and D-cycloserine accelerate learning acquisition in the rat. Neuropharmacology, 2001, 41(4), 517-522. (Pubitemid 32816907)
26. Fontana, D. J.; Daniels, S. E.; Wong, E. H.; Clark, R. D.; Eglen, R. M. The effects of novel, selective 5-hydroxytryptamine (5-HT)4 receptor ligands in rat spatial navigation. Neuropharmacology, 1997, 36(4-5), 689-696.
27. Lelong, V.; Lhonneur, L.; Dauphin, F.; Boulouard, M. BIMU 1 and RS 67333, two 5-HT4 receptor agonists, modulate spontaneous alternation deficits induced by scopolamine in the mouse. Naunyn Schmiedebergs Arch. Pharmacol., 2003, 367(6), 621-628. (Pubitemid 36829461)
28. Marchetti, E.; Dumuis, A.; Bockaert, J.; Soumireu-Mourat, B.; Roman, F. S. Differential modulation of the 5-HT(4) receptor agonists and antagonist on rat learning and memory. Neuropharmacology, 2000, 39(11), 2017-2027. (Pubitemid 30645625)
29. Letty, S.; Child, R.; Dumuis, A.; Pantaloni, A.; Bockaert, J.; Rondouin, G. 5-HT4 receptors improve social olfactory memory in the rat. Neuropharmacology, 1997, 36(4-5), 681-687. (Pubitemid 27272114)
30. Terry, A. V. Jr.; Buccafusco, J. J.; Jackson, W. J.; Prendergast, M. A.; Fontana, D. J.; Wong, E. H.; Bonhaus, D. W.; Weller, P.; Eglen, R. M. Enhanced delayed matching performance in younger and older macaques administered the 5-HT4 receptor agonist, RS 17017. Psychopharmacology (Berl), 1998, 135(4), 407-415.
31. Lamirault, L.; Simon, H. Enhancement of place and object recognition memory in young adult and old rats by RS 67333, a partial agonist of 5-HT4 receptors. Neuropharmacology, 2001, 41(7), 844-853. (Pubitemid 33001418)
32. Levallet, G.; Hotte, M.; Boulouard, M.; Dauphin, F. Increased particulate phosphodiesterase 4 in the prefrontal cortex supports 5-HT4 receptor-induced improvement of object recognition memory in the rat. Psychopharmacology (Berl), 2009, 202(1-3), 125-139.
33. Cho, S.; Hu, Y. Activation of 5-HT4 receptors inhibits secretion of beta-amyloid peptides and increases neuronal survival. Exp. Neurol., 2007, 203(1), 274-278. (Pubitemid 44821167)
34. Robert, S. J.; Zugaza, J. L.; Fischmeister, R.; Gardier, A. M.; Lezoualc'h, F. The human serotonin 5-HT4 receptor regulates secretion of non-amyloidogenic precursor protein. J. Biol. Chem., 2001, 276(48), 44881-44888. (Pubitemid 37391275)
35. Lezoualc'h, F. 5-HT4 receptor and Alzheimer's disease: the amyloid connection. Exp. Neurol., 2007, 205(2), 325-329.
36. Lucas, G.; Rymar, V. V.; Du, J.; Mnie-Filali, O.; Bisgaard, C.; Manta, S.; Lambas-Senas, L.; Wiborg, O.; Haddjeri, N.; Pineyro, G.; Sadikot, A. F.; Debonnel, G. Serotonin(4) (5-HT(4)) receptor agonists are putative antidepressants with a rapid onset of action. Neuron, 2007, 55(5), 712-725.
37. Erspamer, V.; Roseghini, M.; Endean, R.; Anastasi, A. Biogenic amines and active polypeptides in the skin of Australian amphibians. Nature, 1966, 212(5058), 204.
38. Endo, T.; Minami, M.; Monma, Y.; Saito, H.; Takeuchi, M. Emesis-related biochemical and histopathological changes induced by cisplatin in the ferret. J. Toxicol. Sci., 1990, 15(4), 235-244.
39. Round, A.; Wallis, D. I. The depolarizing action of 5-hydroxytryptamine on rabbit vagal afferent and sympathetic neurones in vitro and its selective blockade by ICS 205-930. Br. J. Pharmacol., 1986, 88(2), 485-494.
40. Ireland, S. J.; Tyers, M. B. Pharmacological characterization of 5-hydroxytryptamine-induced depolarization of the rat isolated vagus nerve. Br. J. Pharmacol., 1987, 90(1), 229-238. (Pubitemid 17235614)
41. Hawthorn, J.; Ostler, K. J.; Andrews, P. L. The role of the abdominal visceral innervation and 5-hydroxytryptamine Mreceptors in vomiting induced by the cytotoxic drugs cyclophosphamide and cis-platin in the ferret. Q. J. Exp. Physiol., 1988, 73(1), 7-21.
42. Nakayama, H.; Yamakuni, H.; Higaki, M.; Ishikawa, H.; Imazumi, K.; Matsuo, M.; Mutoh, S. Antiemetic activity of FK1052, a 5-HT3- and 5-HT4-receptor antagonist, in Suncus murinus and ferrets. J. Pharmacol. Sci., 2005, 98(4), 396-403. (Pubitemid 41297013)
43. Crowell, M. D.; Mathis, C.; Schettler, V. A.; Yunus, T.; Lacy, B. E. The effects of tegaserod, a 5-HT receptor agonist, on gastric emptying in a murine model of diabetes mellitus. Neurogastroenterol. Motil., 2005, 17(5), 738-743.
44. James, A. N.; Ryan, J. P.; Crowell, M. D.; Parkman, H. P. Regional gastric contractility alterations in a diabetic gastroparesis mouse model: effects of cholinergic and serotoninergic stimulation. Am. J. Physiol. Gastrointest. Liver Physiol., 2004, 287(3), G612-619.
45. Asakawa, A.; Ueno, N.; Katagi, M.; Ijuin, Y.; Morita, Y.; Mizuno, S.; Inui, T.; Sakamaki, R.; Shinfuku, N.; Uemoto, M. Mosapride improves food intake, while not worsening glycemic control and obesity, in ob/ob obese mice with decreased gastric emptying. J. Diabetes Complications, 2006, 20(1), 56-58. (Pubitemid 43028415)
46. Mikami, T.; Ochi, Y.; Suzuki, K.; Saito, T.; Sugie, Y.; Sakakibara, M. 5-Amino-6-chloro-N-[(1-isobutylpiperidin-4-yl)methyl]-2-methylimidazo[1,2- alpha]pyridine-8-carboxamide (CJ-033,466), a novel and selective 5-hydroxytryptamine4 receptor partial agonist: pharmacological profile in vitro and gastroprokinetic effect in conscious dogs. J. Pharmacol. Exp. Ther., 2008, 325(1), 190-199. (Pubitemid 351439166)
47. Beattie, D. T.; Armstrong, S. R.; Shaw, J. P.; Marquess, D.; Sandlund, C.; Smith, J. A.; Taylor, J. A.; Humphrey, P. P. The in vivo gastrointestinal activity of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch. Pharmacol., 2008, 378(1), 139-147.
48. Becker, D. P.; Flynn, D. L.; Shone, R. L.; Gullikson, G. Azaadamantane benzamide 5-HT4 agonists: gastrointestinal prokinetic SC-54750. Bioorg. Med. Chem. Lett., 2004, 14(22), 5509-5512. (Pubitemid 39346335)
49. Tazawa, S.; Masuda, N.; Koizumi, T.; Kitazawa, M.; Nakane, T.; Miyata, H. KDR-5169, a new gastrointestinal prokinetic agent, enhances gastric contractile and emptying activities in dogs and rats. Eur. J. Pharmacol., 2002, 434(3), 169-176. (Pubitemid 34056576)
50. Rao, S. S. Constipation: evaluation and treatment of colonic and anorectal motility disorders. Gastrointest. Endosc. Clin. N. Am., 2009, 19(1), 117-139.
51. Pohl, D.; Tutuian, R.; Fried, M. Pharmacologic treatment of constipation: what is new? Curr. Opin. Pharmacol., 2008, 8(6), 724-728.
52. Kim, H. S.; Choi, E. J.; Park, H. The effect of mosapride citrate on proximal and distal colonic motor function in the guinea-pig in vitro. Neurogastroenterol. Motil., 2008, 20(2), 169-176.
53. Liu, Z.; Sakakibara, R.; Odaka, T.; Uchiyama, T.; Yamamoto, T.; Ito, T.; Asahina, M.; Yamaguchi, K.; Yamaguchi, T.; Hattori, T. Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients. Mov. Disord., 2005, 20(6), 680-686. (Pubitemid 41051779)
54. Quigley, E. M.; Vandeplassche, L.; Kerstens, R.; Ausma, J. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation. A 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol. Ther., 2009, 29(3), 315-328.
55. Tack, J.; van Outryve, M.; Beyens, G.; Kerstens, R.; Vandeplassche, L. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut, 2009, 58(3), 357-365.
56. Thompson, C. A. Novartis suspends tegaserod sales at FDA's request. Am. J. Health Syst. Pharm., 2007, 64(10), 1020.
57. Mayer, E. A. Clinical practice. Irritable bowel syndrome. N. Engl. J. Med., 2008, 358(16), 1692-1699.
58. Camilleri, M. Serotonin in the gastrointestinal tract. Curr. Opin. Endocrinol. Diabetes Obes., 2009, 16(1), 53-59.
59. Garvin, B.; Wiley, J. W. The role of serotonin in irritable bowel syndrome: implications for management. Curr. Gastroenterol. Rep., 2008, 10(4), 363-368.
60. Fayyaz, M.; Lackner, J. M. Serotonin receptor modulators in the treatment of irritable bowel syndrome. Ther. Clin. Risk Manag., 2008, 4(1), 41-48. (Pubitemid 351460929)
61. Evans, B. W.; Clark, W. K.; Moore, D. J.; Whorwell, P. J. Tegaserod for the treatment of irritable bowel syndrome. Cochrane Database Syst. Rev., 2004, (1), CD003960.
62. Scarpellini, E.; Tack, J. Renzapride: a new drug for the treatment of constipation in the irritable bowel syndrome. Expert Opin. Investig. Drugs, 2008, 17(11), 1663-1670.
63. D'Agostino, G.; Condino, A. M.; Gallinari, P.; Franceschetti, G. P.; Tonini, M. Characterization of prejunctional serotonin receptors modulating [3H]acetylcholine release in the human detrusor. J. Pharmacol. Exp. Ther., 2006, 316(1), 129-135. (Pubitemid 41832589)
64. Darblade, B.; Behr-Roussel, D.; Gorny, D.; Lebret, T.; Benoit, G.; Hieble, J. P.; Brooks, D.; Alexandre, L.; Giuliano, F. Piboserod (SB 207266), a selective 5-HT4 receptor antagonist, reduces serotonin potentiation of neurally-mediated contractile responses of human detrusor muscle. World J. Urol., 2005, 23(2), 147-151.
65. Clark, R. D.; Jahangir, A.; Alam, M.; Rocha, C.; Lin, L.; Bjorner, B.; Nguyen, K.; Grady, C.; Williams, T. J.; Stepan, G.; Tang, H. M.; Ford, A. P. Identification of a 5-HT4 receptor antagonist clinical candidate through side-chain modification. Bioorg. Med. Chem. Lett., 2005, 15(6), 1697-1700.
66. Rahme, M. M.; Cotter, B.; Leistad, E.; Wadhwa, M. K.; Mohabir, R.; Ford, A. P.; Eglen, R. M.; Feld, G. K. Electrophysiological and antiarrhythmic effects of the atrial selective 5-HT(4) receptor antagonist RS-100302 in experimental atrial flutter and fibrillation. Circulation, 1999, 100(19), 2010-2017.
67. Lefebvre, H.; Dhib, M.; Godin, M.; Contesse, V.; Delarue, C.; Rieu, M.; Wolf, L. M.; Vaudry, H.; Kuhn, J. M. Effect of the serotonin 5-HT4 receptor agonist cisapride on aldosterone secretion in corticotropic insufficiency and primary hyperaldosteronism. Neuroendocrinology, 1997, 66(3), 229-233.
68. Lefebvre, H.; Contesse, V.; Delarue, C.; Feuilloley, M.; Hery, F.; Grise, P.; Raynaud, G.; Verhofstad, A. A.; Wolf, L. M.; Vaudry, H. Serotonin-induced stimulation of cortisol secretion from human adrenocortical tissue is mediated through activation of a serotonin4 receptor subtype. Neuroscience, 1992, 47(4), 999-1007.
69. Lefebvre, H.; Cartier, D.; Duparc, C.; Lihrmann, I.; Contesse, V.; Delarue, C.; Godin, M.; Fischmeister, R.; Vaudry, H.; Kuhn, J. M. Characterization of serotonin(4) receptors in adrenocortical aldosterone-producing adenomas: in vivo and in vitro studies. J. Clin. Endocrinol. Metab., 2002, 87(3), 1211-1216.
70. Espejo, E. F.; Gil, E. Antagonism of peripheral 5-HT4 receptors reduces visceral and cutaneous pain in mice, and induces visceral analgesia after simultaneous inactivation of 5-HT3 receptors. Brain Res., 1998, 788(1-2), 20-104 (Pubitemid 28202139)
71. Hinschberger, A.; Butt, S.; Lelong, V.; Boulouard, M.; Dumuis, A.; Dauphin, F.; Bureau, R.; Pfeiffer, B.; Renard, P.; Rault, S. New benzo[h][1,6]naphthyridine and azepino[3,2-c]quinoline derivatives as selective antagonists of 5-HT4 receptors: binding profile and pharmacological characterization. J. Med. Chem., 2003, 46(1), 138-147. (Pubitemid 36043793)
72. Ueno, N.; Satoh, Y. Rapid effect of mosapride citrate, 5-HT4 receptor agonist, on fasting blood glucose in Type 2 diabetes patients. J. Diabetes Complications, 2008, 23(4), 255-256
73. Ueno, N.; Inui, A.; Asakawa, A.; Takao, F.; Komatsu, Y.; Kotani, K.; Nishimura, R.; Kasuga, M., Mosapride, a 5HT-4 receptor agonist, improves insulin sensitivity and glycaemic control in patients with Type II diabetes mellitus. Diabetologia, 2002, 45(6), 792-797.
74. Pinder, R. M.; Brogden, R. N.; Sawyer, P. R.; Speight, T. M.; Avery, G. S. Metoclopramide: a review of its pharmacological properties and clinical use. Drugs, 1976, 12(2), 81-131.
75. Keller, A.; Elz, S.; Schunack, W. Metoclopramide. Leading structure for 5-HT3 and 5-HT4 receptor ligands. Pharm. Ztg., 1998, 143, 2537-2545.
76. Prieto, J.; Moragues, J.; Spickett, R. G.; Vega, A.; Colombo, M.; Salazar, W.; Roberts, D. J. Synthesis and pharmacological properties of a series of antidopaminergic piperidyl benzamides. J. Pharm. Pharmacol., 1977, 29(3), 147-152.
77. Langlois, M.; Fischmeister, R. 5-HT4 receptor ligands: applications and new prospects. J. Med. Chem., 2003, 46(3), 319-344. (Pubitemid 36139783)
78. McCallum, R. W.; Prakash, C.; Campoli-Richards, D. M.; Goa, K. L. Cisapride. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use as a prokinetic agent in gastrointestinal motility disorders. Drugs, 1988, 36(6), 652-681.
79. Briejer, M. R.; Akkermans, L. M.; Schuurkes, J. A. Gastrointestinal prokinetic benzamides: the pharmacology underlying stimulation of motility. Pharmacol. Rev., 1995, 47(4), 631-651.
80. Smith, W. W.; Sancilio, L. F.; Owera-Atepo, J. B.; Naylor, R. J.; Lambert, L. Zacopride, a potent 5-HT3 antagonist. J. Pharm. Pharmacol., 1988, 40(4), 301-302.
81. Flynn, D. L.; Zabrowski, D. L.; Becker, D. P.; Nosal, R.; Villamil, C. I.; Gullikson, G. W.; Moummi, C.; Yang, D. C. SC-53116: the first selective agonist at the newly identified serotonin 5-HT4 receptor subtype. J. Med. Chem., 1992, 35(8), 1486-1489.
82. Briejer, M. R.; Akkermans, L. M.; Meulemans, A. L.; Lefebvre, R. A.; Schuurkes, J. A. Cisapride and a structural analogue, R 76, 186, are 5-hydroxytryptamine4 (5-HT4) receptor agonists on the guineapig colon ascendens. Naunyn Schmiedebergs Arch. Pharmacol., 1993, 347(5), 464-470.
83. Irwin, I.; Palme, M.; Becker, C. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders. PCT Pat. Appl., WO2005068461. 2005.
84. Harada, H.; Yamazaki, H.; Toyotomi, Y.; Tateishi, H.; Mine, Y.; Yoshida, N.; Kato, S. Novel N-[1-(1-substituted 4-piperidinylmethyl)-4-piperidinyl] benzamides as potent colonic prokinetic agents. Bioorg. Med. Chem. Lett., 2002, 12(6), 967-970.
85. Kato, S.; Yamazaki, H.; Hirokawa, Y.; Suga, Y.; Yoshida, N.; Morikage, S.; Morikage, K.; Oku, S. 1,4-disubstituted piperidine derivative and medicinal composition containing the same. Jap. Pat. Appl., JP2004277320. 2004.
86. Becker, D. P.; Flynn, D. L.; Moormann, A. E.; Nosal, R.; Villamil, C. I.; Loeffler, R.; Gullikson, G. W.; Moummi, C.; Yang, D. C. Pyrrolizidine esters and amides as 5-HT4 receptor agonists and antagonists. J. Med. Chem., 2006, 49(3), 1125-1139.
87. Becker, D. P.; Flynn, D. L.; Villamil, C. I. Bridgehead-methyl analog of SC-53116 as a 5-HT4 agonist. Bioorg. Med. Chem. Lett., 2004, 14(12), 3073-3075.
88. Itoh, Y.; Kato, H.; Yasuda, S.; Iwasaki, N.; Nishino, H.; Takeshita, M. Benzamide derivative. PCT Pat. Appl., WO9214705. 1992.
89. Itoh, K.; Sonda, S.; Kawahara, T.; Asano, K.; Kawakita, T. Benzoic acid compounds and medicinal use thereof. PCT Pat. Appl., WO9711054. 1997.
90. Itoh, K.; Kanzaki, K.; Ikebe, T.; Kuroita, T.; Tomozane, H.; Sonda, S.; Sato, N.; Haga, K.; Kawakita, T. Synthesis and pharmacological evaluation of carboxamide derivatives as selective serotoninergic 5-HT4 receptor agonists. Eur. J. Med. Chem., 1999, 34(11), 977-989.
91. Sonda, S.; Kawahara, T.; Katayama, K.; Sato, N.; Asano, K. Synthesis and pharmacological evaluation of benzamide derivatives as selective 5-HT(4) receptor agonists. Bioorg. Med. Chem., 2005, 13(9), 3295-3308.
92. Suzuki, T.; Imanishi, N.; Itahana, H.; Kamato, T.; Miyata, K. Novel benzamide derivative and medicinal composition containing the same. PCT Pat. Appl., WO9518104. 1995.
93. Takadoi, M.; Kobayashi, F.; Sekiguchi, H. Novel benzamide derivatives. PCT Pat. Appl., WO9710207, 1997.
94. Baba, Y.; Usui, T.; Kakiue, T.; Ozeki, Y.; Tsukamoto, K.; Asaeda, N.; Ito, N. Benzopyrane carboxamide derivative, its salt and production method and use. Jap. Pat. Appl., JP8073463, 1996.
95. Kakigami, T.; Usui, T.; Ikami, T.; Tsukamoto, K.; Miwa, Y.; Taga, T.; Kataoka, T. Serotonin 5-HT4 receptor agonistic activity of the optical isomers of (+/-)-4-amino-N-[2-(1-azabicyclo[3.3.0]octan-5-yl)ethyl]-5-chloro-2,3- dihydro-2-methylbenzo[b]furan-7-carboxamide. Chem. Pharm. Bull., 1998, 46(6), 1039-1043. (Pubitemid 28363335)
96. Kakigami, T.; Usui, T.; Tsukamoto, K.; Kataoka, T. Synthesis and structure-activity relationship of 3-Substituted benzamide, benzo [b]furan-7-carboxamide, 2, 3-dihydrobenzo[b]furan-7-carboxamide, and Indole-5-carboxamide derivatives as selective serotonin 5-HT4 receptor agonists. Chem. Pharm. Bull., 1998, 46(1), 42-52.
97. Van Daele, G.; Bosmans, J.-P.; Schuurkes, J. Enterokinetic benzamides. PCT Pat. Appl., WO96016060, 1996.
98. Ahmed, M.; Miller, N. D.; Milner, P. H.; Moss, S.; Thompson, M. 4-amino-benzamide derivatives as 5-HT4 receptor agonists for the treatment of gastrointestinal, neurological and cardiovascular disorders. PCT Pat. Appl. WO2007048643, 2007.
99. Prins, N. H.; Van Haselen, J. F.; Lefebvre, R. A.; Briejer, M. R.; Akkermans, L. M.; Schuurkes, J. A. Pharmacological characterization of 5-HT4 receptors mediating relaxation of canine isolated rectum circular smooth muscle. Br. J. Pharmacol., 1999, 127(6), 1431-1437.
100. Ahmed, M.; Miller, N. D.; Moss, S.; Sanger, G. 5-amino-6-bromo-N-[1- (tetrahydro-2H-pyran-4-ylmethyl) -4-piperidinyl] methyl-3, 4 -dihydro-2H-chromene-8-carboxamide as 5-HT4 receptor agonist. PCT Pat. Appl., WO2007096352, 2007.
101. Rabasseda, X.; Graul, A.; Silvestre, J.; Castaner, J. Cilansetron. Drugs Future, 1999, 24, 475.
102. Langlois, M.; Zhang, L.; Brémont, B.; Shen, S.; Manara, L.; Croci, T. Design of a potent 5-HT4 receptor agonist with nanomolar affinity. Bioorg. Med. Chem. Lett., 1994, 4(12), 1433-1436. (Pubitemid 24208308)
103. Fancelli, D.; Caccia, C.; Severino, D.; Vaghi, F.; Varasi, M. Substituted dihydrobenzofuran derivatives as 5-HT4 agonists. PCT Pat. Appl., WO9633186. 1996.
104. Lochead, A.; Jegham, S.; Nedelec, A.; Solignac, A. 1,4-diazabicyclo [2.2.2] oct-2-ylmethyl derivatives, their preparation and therapeutic application. PCT Pat. Appl., WO9824790, 1998.
105. Suzuki, T.; Iwaoka, K.; Imanishi, N.; Kamato, T.; Miyata, K.; Ohta, M. Oxadiazole derivative and medicinal composition thereof. PCT Pat. Appl., WO9532965, 1995.
106. Nagakura, Y.; Akuzawa, S.; Miyata, K.; Kamato, T.; Suzuki, T.; Ito, H.; Yamaguchi, T. Pharmacological properties of a novel gastrointestinal prokinetic benzamide selective for human 5-HT4 receptor versus human 5-HT3 receptor. Pharmacol. Res., 1999, 39(5), 375-382. (Pubitemid 29263905)
107. Suzuki, T.; Iwaoka, K.; Imanishi, N.; Nagakura, Y.; Miyata, K.; Nakahara, H.; Ohta, M.; Mase, T. Synthesis of the selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist (+)-(S)-2-chloro-5-methoxy-4-[5-(2-piperidylmethyl)-1,2,4- oxadiazol-3-yl]aniline. Chem. Pharm. Bull., 1999, 47(1), 120-122. (Pubitemid 29078744)
108. Druzgala, P. Stereoisomeric pyridyl and pyridonyl compounds and methods for the treatment of gastrointestinal and central nervous system disorders. PCT Pat. Appl., WO2007005951, 2007.
109. Gastrointestinal drugs. Drug Data Rep., 2005, 27(7), 633.
110. Moser, P. C.; Bergis, O. E.; Jegham, S.; Lochead, A.; Duconseille, E.; Terranova, J.-P.; Caille, D.; Berque-Bestel, I.; Lezoualc'h, F.; Fischmeister, R.; Dumuis, A.; Bockaert, J.; George, P.; Soubrie, P.; Scatton, B. SL65.0155, A Novel 5-Hydroxytryptamine4 Receptor Partial Agonist with Potent Cognition-Enhancing Properties. J. Pharmacol Exp. Ther., 2002, 302(2), 731-741.
111. Kikuchi, H.; Satoh, H.; Fukutomi, R.; Inomata, K.; Suzuki, M.; Ueno, M.; Hagihara, K.; Arai, T.; Eguchi, H.; Noguchi, Y. Accelerator for digestive tract movement. PCT Pat. Appl, WO9503045. 1995.
112. Marquess, D.; Choi, S.-K.; Fatheree, P. R.; Gendron, R.; Goldblum, A. A.; Long, D. D.; Turner, S.; Liu, J. Indazole-carboxamide compounds as 5-ht4 receptor agonists. PCT Pat. Appl, WO2005080389. 2005.
113. Noguchi, H.; Sakurada, I.; Uchida, C.; Waizumi, N. Benzisoxazole derivatives. PCT Pat. Appl, WO2006090224. 2006.
114. Ohuchi, Y.; Suzuki, M.; Asanuma, H.; Yokomori, S.; Hatayama, K.; Isobe, Y.; Ito, C.; Muramatsu, M. Heterocyclic compound. PCT Pat. Appl. W09412497, 1994.
115. Ohuchi, Y.; Suzuki, M,; Asanuma, H.; Yokomori, S.; Hatayama, K. Quinolinecarboxylic acid derivative. PCT Pat. Appl, W09531455. 1995.
116. Marquess, D.; Fatheree, P.; Turner, S.; Long, D.; Choi, S.-K.; Goldblum, A.; Genov, D. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists. PCT Pat. Appl, WO2005100350. 2005.
117. Mohler, E. G.; Shacham, S.; Noiman, S.; Lezoualc'h, R; Robert, S.; Gastineau, M.; Rutkowski, J.; Marantz, Y.; Dumuis, A.; Bockaert, J.; Gold, P. E.; Ragozzino, M. E. VRX-03011, a novel 5-.HT4 agonist, enhances memory and hippocampal acetylcholine efflux. Neuropharmacol, 2007, 53(4), 563-573.
118. Bar-Haim, S.; Becker, O.; Chen, D.; Dhanoa, D.; Heifetz, A.; Lobera, M.; Marantz, Y.; Mohanty, P.; Noiman, S.; Shachem, S.; Wu, L. Thienopyridinone compounds and methods of treatment. PCT Pat. Appl, WO2005121151. 2005.
119. Dumuis, A.; Sebben, M.; Monfermi, E.; Nicola, M.; Turconi, M.; Ladinsky, H.; Bockaert, J., Azabicycloalkyl benzimidazolone derivatives as a novel class of potent agonists at the 5-HT4 receptor positively coupled to adenylate cyclase in brain. Naunyn Schmiedebergs Arch, Pharmacol, 1991, 343(3), 245-251.
120. Flynn, D. Lee; Moormann, A. Benzimidazole compounds. PCT Pat Appl, WO9400449.1994.
121. Flynn, D.; Moormann, A.; Becker, D.; Dappen, M.; Nosal, R.; Shone, R.; Villamil, C. Benzimidazole compounds. PCT Pat. Appl, WO9400454. 1994.
122. Becker, D.; Flynn, D.; Villamil, C. Indolones useful as serotonergic agents. US Pat. Appl, US5399562. 1994.
123. Mckinnell, R.; Gendron, R.; Jiang, L.; Choi, S.-K.; Long, D.; Fatheree, P.; Marquess, D.; Dalziel, S.; Phizackerley, K. Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists. PCT Pat. Appl, WO2006127815. 2006.
124. Toga, T.; Kohmura, Y.; Kawatsu, R. The 5-HT(4) agonists cisapride, mosapride, and CJ-033466, a Novel potent compound, exhibit different human ether-a-go-go-related gene (hERG)blocking activities. J. Pharmacol. Sci. 2007, 105(2), 207-210. (Pubitemid 350106811)
125. Fenwick, D.; Gymer, G.; Noguchi, H.; Stobie, A.; Uchida, C. Imidazopyridine compounds as 5-HT4 receptor modulators. PCT Pat. Appl, WO2003035649. 2003.
126. Iguchi, S.; Katsu, Y.; Kon-I, K.; Noguchi, H.; Uchida, C. Imidazopyridine compounds as 5-HT4 receptor agonists. PCT Pat. Appl, WO2004026869. 2004.
127. Katsu, Y.; Kon-I, K.; Morita, M.; Noguchi, H.; Uchida, C. Nsubstituted piperidinyl-imidazopyridine compounds as 5-HT4 receptor modulators. PCT Pat. Appl, WO0426868. 2004.
128. Noguchi, H.; Uchida, C. Imidazopyridine compounds having 5HT4 receptor agonistic activity and 5-HT3 receptor antagonistic activity. PCT Pat. Appl, WO0494418. 2004.
129. Koshimura, H.; Suzuki, K.; Kumazawa, T.; Takai, H.; Yokoyama, T.; Kusaka, H.; Nosaka, C.; Ichimura, M.; Watanabe, F.; Kishibayashi, N.; Karasawa, A. Quinazoline derivatives. PCT Pat. Appl, WO9950264. 1999.
130. Buchheit, K. H.; Gamse, R.; Giger, R.; Hoyer, D.; Klein, F.; Kloppner, E.; Pfannkuche, H. J.; Mattes, H. The serotonin 5-HT4 receptor. 2. Structure-activity studies of the indole carbazimidamide class of agonists. J. Med. Chem., 1995, 38(13), 2331-2338.
131. Buchheit, K. H.; Gamse, R.; Giger, R.; Hoyer, D.; Klein, F.; Kloppner, E.; Pfannkuche, H. J.; Mattes, H. The serotonin 5-HT4 receptor. 1. Design of a new class of agonists and receptor map of the agonist recognition site. J. Med. Chem., 1995, 38(13), 23262330.
132. Beattie, D. T.; Smith, J. A.; Marquess, D.; Vickery, R. G.; Armstrong, S. R.; Pulido-Rios, T.; McCullough, J. L.; Sandlund, C.; Richardson, C.; Mai, N.; Humphrey, P. P. The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo. Br. J. Pharmacol, 2004, 143(5), 549-560.
133. Monge, A.; Pena, M. C; Palop, J. A.; Caldero, J. M.; Roca, J.; Garcia, E.; Romero, G.; del Rio, J.; Lasheras, B. Synthesis of 2piperazinylbenzothiazole and 2-piperazinylbenzoxazole derivatives with 5-HT3 antagonist and 5-HT4 agonist properties. J. Med. Chem., 1994, 37(9), 1320-1325. (Pubitemid 24179474)
134. Kato, M.; Nishino, S.; Takasugi, H. Pyrrolobenzoxazine derivatives as 5-HT agonists and antagonists. PCT Pat. Appl, WO9306108. 1993.
135. Dumuis, A.; Ansanay, H.; Waeber, C.; Sebben, M.; Fagni, L.; Bockaert, J. Serotonin receptors and their ligands. In: Pharmacochemistry Library, Elsevier Science B.V. Amsterdam, 1997, Vol, 27, p 261.
136. Grossman, C. J.; Kilpatrick, G. J.; Bunce, K. T. Development of a radioligand binding assay for 5-HT4 receptors in guinea-pig and rat brain. Br. J. Pharmacol, 1993, 109(3), 618-624. (Pubitemid 23181036)
137. Candura, S. M.; Messori, E.; Franceschetti, G. P.; D'Agostino, G.; Vicini, D.; Tagliani, M.; Tonini, M. Neural 5-HT4 receptors in the human isolated detrusor muscle: effects of indole, benzimidazolone and substituted, benzamide agonists and antagonists. Br. J. Pharmacol, 1996, 118(8), 1965-1970. (Pubitemid 26292564)
138. Oxford, A.; Whitehead, J.; Knight, J. 3-piperidinylmethylcarboxylate substituted indoles. PCT Pat. Appl, WO1992014727. 1992.
139. Cereda, E.; Bignotti, M.; Martino, V.; Schiavi, G. B.; Sagrada, A. Preparation of l-substituted-piperidin-4-yl.methyl esters and amides as 5-HT4 antagonists. PCT Pat. Appl, W09628424. 1996.
140. Gaster, L. M.; Joiner, G. P.; King, F. D.; Wyman, P. A.; Sutton, J. M.; Bingham, S.; Ellis, E. S.; Sanger, G. J.; Wardle, K. A. N-[(1butyl-4- piperidinyl)meth.yl]-3,4dihydro-2H-[l,3]oxazino[3,2a]indole 10-carboxamide hydrochloride: the first potent and selective 5-HT4 receptor antagonist amide with oral activity. J. Med. Chem., 1995, 38(24), 4760-4763.
141. Buxton, P.; Groves, S.; Thomson, S.; Van Schie, D.; Yeates, K. Pharmaceutical composition comprising N- ((l-N-butyl-4-piperidinyl) methyl)-3, 4-dihydro-2H- (1, 3) oxazino (3, 2-a) indole-10carboxamide or salt and process therefor comprising dry granulation. PCT Pat. Appl, WO2003068193. 2003.
142. Guglielmotti, A.; Polenzani, L.; Alisi, A.; Cazzolla, N. Use of 2H[1, 3] - oxazino [3, 2-a] indole derivatives for the treatment of neuropathic pain, PCT Pat. Appl, WO2005014001. 2005.
143. Hossner, F.; Ryan, D. A. 3,4-dihydro -N-[[l-(3 -hydroxybutyl) -4piperidinyl] methyl] -2H-[1,3] oxazino[3, 2-a]indole -10carboxamide as 5-HT(4) receptor antagonist. PCT Pat. Appl, WO00l7207. 2000.
144. Gaster, L.; Wyman, P. A. Condensed indole derivatives as 5-HT4receptor antagonists. PCT Pat. Appl, WO9504737. 1995.
145. King, D.; Gaster, L.; Mulholland, K. 5-HT4 receptor antagonists. PCT Pat. Appl, WO9427987. 1994.
146. Buchheit, K. H. ; Klein, F.; Kloppner, E.; Pfannkuche, H. J.; Mattes, H. The serotonin 5-HT4 receptor: Part 3: Design and pharmacological evaluation of a new class of antagonists. Bioorg. Med. Chem. Lett, 1995, 5(21), 2495-2500.
147. Sanger, G.; King, F.; Baxter, G.; Gaster, L.; Kaumann, A.; Kennett, G.; Mulholland, K.; Vimal, M.; Wardle, K.; Wyman, P.; Young, R. 5-HT4 receptor antagonists. PCT Pat. Appl, WO9302677. 1993.
148. King, F.; Gaster, L.; Joiner, G. Imidazopyridines and indolizines as 5-HT4 antagonists. PCT Pat. Appl, WO9308187. 1993.
149. King, F.; Gaster, L.; Wyman, P.; Joiner, G. 5-HT4 receptor antagonits. PCT Pat, Appl, WO9407859. 1994.
150. King, F.; Gaster, L. Imidazopyridine derivatives as 5-HT4 Receptor antagonists. PCT Pat. Appl, WO9408998. 1994.
151. King, F.; Gaster, L.; Joiner, G.; Mulholland, K.; Rahman, S. Heterocyclic esters or amides used as 5-HT4 receptor antagonists. PCT Pat Appl, WO9408994. 1994.
152. Buchheit, K. H.; Gamse, R.; Pfannkuche, H. J. SDZ 205-557, a selective antagonist at 5-HT4 receptors in the isolated guinea pig ileum, Eur. J. Pharmacol, 1991,200(2-3), 373-1274
153. Yang, D.; Soulier, J. L.; Sicsic, S.; Mathe-Allainmat, M.; Bremont, B.; Croci, T.; Cardamone, R.; Aureggi, G.; Langlois, M. New esters of 4-amino-5-chlo.ro-2-methoxybenzoic acid as potent agonists and antagonists for 5-HT4 receptors. J. Med. Chem., 1997, 40(4), 608-621. (Pubitemid 27080041)
154. Blondel, O.; Gastineau, M.; Langlois, M.; Fischmeister, R. The 5HT4 receptor antagonist ML10375 inhibits the constitutive activity of human 5-HT4(c) receptor. Br. J. Pharmacol, 1998, 125(4), 595597. (Pubitemid 28482595)
155. Gaster, L. M.; Jennings, A. J.; Joiner, G. F.; King, F. D.; Mulholland, K. R.; Rahman, S. K.; Starr, S.; Wyman, P. A.; Wardle, K, A.; Ellis, E. S. (l-Butyl.-4-piperidinyl)methyl 8-amino7-chloro-l,4-benzodioxane-5-carboxylate hydrochloride: a highly potent and selective 5-HT4 receptor antagonist derived from metoclopramide. J. Med. Chem., 1993, 36(25), 4121-4123.
156. Clark, R. D.; Jahangir, A.; Flippin, L. A.; Langsten, J. A.; Leung, E.; Bonhaus, D. W.; Wong, E. H. F.; Johnson, L. G.; Eglen, R. M. RS-100235: A high affinity 5-HT4 receptor antagonist. Bioorg. Med. Chem. Lett., 1995, 5(18), 2119-2122.
157. King, F. D.; Gaster, L. M.; Joiner, G. F. Preparation of benzopyran, benzothiopyran and benzofuran derivatives as 5-HT4 antagonists. PCT Pat. Appl, WO9316072. 1993.
158. King, F.; Gaster, L.; Mulholland, K. Heteroaryl compounds used as pharmaceuticals. PCT Pat, Appl, WO9405654. 1994.
159. Gaster, L.; Wyman, P. Piperidine derivatives as 5-HT4 receptor antagonists. PCT Pat. Appl, WO9410174. 1994.
160. Gaster, L. M. 8-amino-7-chloro-l,4-benzodioxan-5-carboxylic acid, -l-butyl-4-piperidmyl ester as a 5-HT4-receptor antagonist. PCT Pat. Appl, WO9429298. 1994.
161. Clark, R.; Eglen, R.; Jahangir, A.; Miller, A.; Gardner, J. Novel 1phenylalkanone 5-HT4 receptor ligands. PCT Pat. Appl, WO9427965. 1995.
162. Clark, R. D.; Jahangir, A.; Langsten, J. A.; Weinhardt, K. K.; Miller, A. B.; Leung, E.; Bonhaus, D. W.; Wong, E. H. F.; Eglen, R. M. Synthesis and preliminary pharmacological evaluation of 2benzyloxy substituted aryl ketones as 5-HT4 receptor antagonists. Bioorg. Med, Chem. Lett, 1994, 4(20), 2481-2484.
163. Hegde, S. S.; Bonhaus, D. W.; Johnson, L. G.; Leung, E.; Clark, R. D.; Eglen, R. M. RS 39604: a potent, selective and orally active 5HT4 receptor antagonist. Br. J. Pharmacol, 1995, 115(6) 10871095.
164. Gaster, L.; Mulholland, K. Heterocyclic condensed benzoic acid derivatives as 5-HT4 receptor antagonists. PCT Pat. Appl, WO9408995. 1994.
165. Clark, R.; Jahangir, A. Dihydrobenzodioxine carboxamide and ketone derivatives as 5-HT4 receptor antagonists. PCT Pat. Appl, WO00l5636. 2000.
166. Bosnians, J.-P.; Gijsen, H.; Mevellec, L. Hydroxycarbonylphenyl substituted 4-(aminomethyl)-piperidine benzamides as 5HT4antagonists. PCT Pat. Appl, WO2005003121. 2005.
167. Bosnians, J.-P.; Gijsen, H.; Mevellec, L. Aminosulfonyl substituted 4-(ammomethyl)-piperidme benzamides as 5HT4-antagonists. PCT Pat. Appl, WO2005000837. 2005.
168. Bosnians, J.-P.; Gijsen, H.; Mevellec, L. 4-(aminomethyl)-piperidine benzamides as 5HT4-antagonists PCT Pat. Appl, WO2005000838. 2005.
169. Bosnians, J.-P.; Gijsen, H.; Mevellec, L. Heterocyclic substituted 4-(aminomethyl)-piperidine benzamides as 5HT4-antagonists. PCT Pat. Appl, WO2005003124. 2005.
170. Bosnians, J.-P.; Meulemans, A.; De Cleyn, M.; Gijsen, H. A(aminomethyl)-piperidine benzamides for treating gastrointestinal disorders. PCT Pat Appl, WO0037461. 2000.
171. King, F.; Gaster, L.; Joiner, G.; Rahman, S.; Sanger, G.; Wardle, K.; Baxter, G.; Kennett, G.; Young, R.; Vimal, M.; Kaumann, A. 5HT4 receptor antagonists. PCT Pat. Appl, WO9303725. 1993.
172. Cohen, M. L.; Bloomquist, W.; Schaus, J. M.; Thompson, D. C.; Susemichel, A. D.; Calligaro, D. A.; Cohen, I., LY353433, a potent, orally effective, long-acting 5-HT(4) receptor antagonist: comparison to cisapride and RS23597-190. J. Pharmacol. Exp. Ther., 1996, 277(1), 97-104. (Pubitemid 27169048)
173. Schaus, J. M.; Thompson, D. C.; Bloomquist, W. E.; Susemichel, A. D.; Calligaro, D. O.; Cohen, M, L. Synthesis and StructureActivity Relationships of Potent and Orally Active 5-HT4 Receptor Antagonists : Indazole and. Benzimidazolone Derivatives. J. Med. Chem, 1998, 41(11), 1943-1955. (Pubitemid 28248668)
174. Minami, M.; Endo, T.; Tamakai, H.; Ogawa, T.; Hamaue, N.; Hirafuji, M.; Monma, Y.; Yoshioka, M.; Hagihara, K. Antiemetic effects of N-3389, a newly synthesized 5-HT3 and 5-HT4 receptor antagonist, in ferrets. Eur. J. Pharmacol, 1997, 321(3), 333-342. (Pubitemid 27105936)
175. Even, L.; Gautier, C.; Aletru, M.; Bovy, P. Benzoxazine derivatives, preparation and application in therapy. PCT Pat. Appl., WO9920633. 1999.
176. Zard, L.; Perard, S. Indazole derivatives, preparation and therapeutic application thereof. PCT Pat. Appl, WO0063215. 2000.
177. Bovy, P.; Courtemanche, G.; Crespin, O. Haloimidazole derivatives and their use as muscarinic m3 and serotoninergic 5HT4 receptors. PCT Pat. Appl, WO0164671. 2001.
178. Bertin, J.; Bovy, P.; Courtemanche, G.; Crespin, O.; Defosse, G.; Fett, E. Triazole and tetrazole derivatives, and their therapeutic use. PCT Pat. Appl, WO0046220. 2000.
179. Courtemanche, G.; Even, L.; Defosse, G.; Bertin, J.; Bovy, P. Benzimidazole derivatives, preparation thereof, and therapeutical. uses thereof. PCT Pat. Appl, WO9804546. 1998.
180. Luc, E.; Samir, J.; Gerard, D.; Miche, A. Dérivés de pipéridine, leur procédé de préparation et leur application en therapeutique French Pat. Appl, FR2731708. 1996.
181. Dumuis, A.; Gozlan, H.; Sebben, M.; Ansanay, H.; Rizzi, C. A.; Turconi, M.; Monferini, E.; Giraldo, E.; Schiantarelli, P.; Ladinsky, H. Characterization of a novel 5-HT4 receptor antagonist of the azabicycloalkyl benzimidazolone class: DAU 6285. Naunyn Schmiedebergs Arch. Pharmacol, 1992, 345(3), 264-269.
182. King, F.; Gaster, L.; Wyman, P. Nitrogen containing heterocyclic compounds useful as pharmaceuticals. PCT Pat. Appl, WO9318027. 1993.
183. Cohen, M.; Schaus, J.; Thompson, D. 5HT4 agonists and antagonists. PCT Pat. Appl, W09917772. 1999.
184. Gaster, L.; Joiner, G.; Mulholland, K.; Wyman, P. Nalkylpiperidinyl-4- methyl carboxylic esters/amides of condensed ring systems as 5-HT4 receptor antagonists. PCT Pat. Appl, WO9408965. 1994.
185. Oxford, A. Substituted phenylcarbamates and phenylureas, their preparation and their use as 5-HT antagonists. PCT Pat. Appl, WO9320071. 1993.
186. Kadowaki, M.; Nagakura, Y.; Tomoi, M.; Mori, J.; Kohsaka, M. Effect of FK.1052, a potent 5-hydroxytryptamine3 and 5hydroxytryptamine4 receptor dual antagonist, on colonic function in vivo. J. Pharmacol. Exp. Ther., 1993, 266(l), 74-80. (Pubitemid 23315630)
187. Yamakuni, H.; Sawai, H.; Maeda, Y.; Imazumi, K.; Sakuma, H.; Matsuo, M.; Mutoh, S.; Seki, J. Probable involvement of the 5hydroxytryptamine(4) receptor in methotrexate-induced delayed emesis in dogs. J. Pharmacol Exp. Ther, 2000, 292(3), 10021007.
188. Jegham, S.; Defosse, G.; Purcell, T.; Even, L. Dérivés d'imidazol4-yl-pipéridine, leur préparation et leur application en thérapeutique. Eur. Pat. Appl, EP646583. 1995.
189. Bureau, R.; Daveu, C.; Lemaitre, S.; Dauphin, F.; Landelle, H.; Lancelot, J. C.; Rault, S. Molecular design based on 3Dpharmacophore. Application to 5-HT4 receptor. J. Chem. Inf. Comput. Sci., 2002, 42(4), 962-967. (Pubitemid 35355246)
190. Lemaitre, S.; Lepailleur, A.; Bureau, R.; Butt-Gueulle, S.; LelongBoulouard, V.; Duchatelle, P.; Boulouard, M.; Dumuis, A.; Daveu, C; Lezoualc'h, F.; Pfeiffer, B.; Dauphin, F.; Rault, S. Novel antagonists of serotonin-4 receptors: synthesis and biological evaluation of pyrrolothienopyrazines. Bioorg. Med. Chem., 2009, 17(6), 2607-2622.
191. Lezoualc'h, F.; Jockers, R.; Berque-Bestel, I. Multivalent-based drug design, applied, to serotonin. 5-HT(4) receptor oligomers. Curr. Pharm. Des., 2009, 15(6), 719-729.
192. Bureau, R.; Varin, T.; Lepailleur, A.; Daveu, C.; Lemaitre, S.; Lancelot, J.; Lesnard, A.; Butt Gueulle, S.; Dauphin, F.; Rault, S. Pharmacophores of 5-HT4 Receptor Ligands: Experience of CERMN and Implications for Drag Design. Curr. Comput. Aided Drug Design, 2008, 4, 199-208.
193. Willem Soudijn, I. v. W. A. P. I. Structure-activity relationships of inverse agonists for G-protein-coupled receptors. Med. Res. Rev., 2005, 25(4), 398-426. (Pubitemid 40946534)
194. De Maeyer, J. H.; Prins, N. H.; Schuurkes, J. A.; Lefebvre, R. A. Differential effects of 5-hydroxytryptamine4 receptor agonists at gastric versus cardiac receptors: an operational framework to explain and quantify organ-specific behavior. J. Pharmacol. Exp. Ther, 2006, 317(3), 955-964.
195. Joubert, L.; Claeysen, S.; Sebben, M.; Bessis, A. S.; Clark, R. D.; Martin, R. S.; Bockaert, J.; Dumuis, A. A 5-HT4 receptor transmembrane network implicated in the activity of inverse agonists but not agonists. 7. Biol. Chem., 2002, 277(28), 25502-25511. (Pubitemid 34951865)
196. Claeysen, S.; Sebben, M.; Becamel, C.; Eglen, R. M.; Clark, R. D.; Bockaert, J.; Dumuis, A. Pharmacological properties of 5 Hydroxytryptamine(4) receptor antagonists on constitutively active wild-type and mutated receptors. Mol. Pharmacol, 2000, 58(1), 136-144. (Pubitemid 30452536)
197. Claeysen, S.; Joubert, L.; Sebben, M.; Bockaert, J.; Dumuis, A. A single mutation in the 5-HT4 receptor (5-HT4-R D100(3.32)A) generates a Gs-coupled receptor activated exclusively by synthetic ligands (RASSL). J. Biol. Chem, 2003, 278(2), 699-702.